# Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions

> **NCT00835263** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lamotrigine
- **DRUG:** Lamictal®

## Key facts

- **NCT ID:** NCT00835263
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2002-02
- **Final completion:** 2002-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835263, "Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00835263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*